Keywords: Alios BioPharma, Vertex, License, Nucleotide drug candidates, Hepatitis C
Alios BioPharma licenses two nucleotide drug candidates to Vertex for up to $1.5 billion
Article | 15 June 2011
Vertex Pharmaceuticals (Nasdaq: VRTX) has entered into an exclusive worldwide licensing accord with Alios BioPharma (Nasdaq OB: AAST) that will ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
